Yahoo Finance • 8 days ago
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by... Full story
Yahoo Finance • 28 days ago
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a Research & Development update in Shanghai, China, and v... Full story
Yahoo Finance • last month
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by... Full story
Yahoo Finance • last month
HUTCHMED (HCM [https://seekingalpha.com/symbol/HCM]) has announced [https://seekingalpha.com/pr/20209647-hutchmed-announces-appointment-of-acting-chief-executive-officer] that CEO Weiguo Su will take a leave of absence for health reasons.... Full story
Yahoo Finance • last month
HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave... Full story
Yahoo Finance • 2 months ago
Dublin, Aug. 22, 2025 (GLOBE NEWSWIRE) -- The "Thailand Construction Equipment Market Research Report 2025-2030" has been added to ResearchAndMarkets.com's offering. The Thailand Construction Equipment Market was sized at 14,786 unit... Full story
Yahoo Finance • 2 months ago
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the completion of patient enrollment of SANOVO, a China Phase III study of... Full story
Yahoo Finance • 3 months ago
HONG KONG/SHANGHAI/FLORHAM PARK - HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) will release its financial results for the first half of 2025 on Thursday, August 7, 2025, the biopharmaceutical company announced in a press release. Th... Full story
Yahoo Finance • 3 months ago
HONG KONG - HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) announced Wednesday it has appointed Deutsche Bank AG (ETR:DBKGn), trading as Deutsche Numis, as its joint corporate broker in London with immediate effect. The appointment... Full story
Yahoo Finance • 3 months ago
HONG KONG - China’s National Medical Products Administration (NMPA) has approved the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib) for treating patients with locally advanced or metastatic EGFR mutation-positive non-squa... Full story
Yahoo Finance • 4 months ago
In trading on Monday, shares of HUTCHMED (China) Ltd (Symbol: HCM) crossed above their 200 day moving average of $16.00, changing hands as high as $16.15 per share. HUTCHMED (China) Ltd shares are currently trading up about 4% on the day.... Full story
Yahoo Finance • 5 months ago
Virtual Investor Conferences NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Thursday, May 15, 2025 featuring live webcast presentati... Full story
Yahoo Finance • 7 months ago
HUTCHMED (China) Limited — SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of... Full story
Yahoo Finance • 7 months ago
HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today jo... Full story
Yahoo Finance • last year
HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemeto... Full story
Yahoo Finance • 2 years ago
HUTCHMED (China) Limited HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that under the 2023 simple renewal mechanis... Full story
Yahoo Finance • 2 years ago
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed patient enrollment of a bridging study of tazemetos... Full story
Yahoo Finance • 2 years ago
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Pro... Full story
Yahoo Finance • 2 years ago
— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with sovleplenib known profile — — Plans for regulatory submission underway in China, wh... Full story
Yahoo Finance • 2 years ago
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 09, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I study in China of HMPL-415, an inve... Full story